PubRank

Deanna L Kroetz

Author PubWeight™ 57.66‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A 2003 5.77
2 Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005 2.68
3 Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007 2.68
4 Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009 2.47
5 A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012 1.50
6 Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 2012 1.46
7 Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. Epilepsia 2007 1.43
8 Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos 2007 1.35
9 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011 1.34
10 Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics 2013 1.30
11 Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011 1.29
12 Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 2003 1.25
13 The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 2008 1.23
14 Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 2012 1.22
15 Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet 2007 1.04
16 OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics 2013 1.02
17 Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004 1.02
18 MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet 2006 1.00
19 Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005 0.98
20 Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J Pharmacol Exp Ther 2008 0.96
21 Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One 2009 0.96
22 Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults. PLoS One 2008 0.95
23 Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics 2010 0.93
24 Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther 2008 0.92
25 Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes. J Pharmacol Exp Ther 2003 0.92
26 Abacavir pharmacogenetics--from initial reports to standard of care. Pharmacotherapy 2013 0.92
27 Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling. J Pharmacol Exp Ther 2012 0.92
28 Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol 2006 0.90
29 Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway. Mol Pharmacol 2013 0.89
30 A survey of integral alpha-helical membrane proteins. J Struct Funct Genomics 2009 0.89
31 Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid omega-hydroxylase activity. Am J Physiol Regul Integr Comp Physiol 2002 0.88
32 Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicol Appl Pharmacol 2011 0.88
33 Candidate gene approach for pharmacogenetic studies. Pharmacogenomics 2002 0.87
34 The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 2013 0.85
35 No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 2003 0.84
36 Covalent attachment of the heme prosthetic group in the CYP4F cytochrome P450 family. Biochemistry 2002 0.84
37 CYP4 isoform specificity in the omega-hydroxylation of phytanic acid, a potential route to elimination of the causative agent of Refsum's disease. J Pharmacol Exp Ther 2006 0.84
38 Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? Pharmacogenet Genomics 2013 0.83
39 Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains. Protein Sci 2010 0.83
40 Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics 2014 0.83
41 The effects of ABCB1 3'-untranslated region variants on mRNA stability. Drug Metab Dispos 2007 0.82
42 PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-Binding cassette transporters to the PharmGKB network. Pharmacol Rev 2006 0.79
43 Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. J Antimicrob Chemother 2007 0.78
44 Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine. Genome Biol 2011 0.78
45 Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol 2006 0.77
46 PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. Pharmacogenet Genomics 2015 0.76
47 Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary gamma-linolenic acid. J Pharmacol Exp Ther 2006 0.76
48 PharmGKB summary: abacavir pathway. Pharmacogenet Genomics 2014 0.75
49 Nicotine metabolism in pregnant and nonpregnant rabbits. Nicotine Tob Res 2008 0.75
50 Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. AIDS 2016 0.75
51 MDR1 reference sequence and reference function. Clin Pharmacol Ther 2002 0.75
52 PharmGKB submission update: VI. PMT submissions of genetic variations in neurotransmitter transporters (SLC6, SLC17, and SLC18) to the PharmGKB network. Pharmacol Rev 2006 0.75
53 PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters. Pharmacol Rev 2006 0.75
54 ABCG2 regulatory single-nucleotide polymorphisms alter in-vivo enhancer activity and expression. Pharmacogenet Genomics 2017 0.75